Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

Chronic Inflammatory Disease Clinical Trial

Official title: A Double-blind, Randomized, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single- and Multiple-ascending Doses of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

Status Terminated

Clinical Trial Summary

A Phase 1, first in human (FIH), single-centre, double-blind, randomized, placebo-controlled, dose escalating trial to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of CBS001 in healthy subjects. The study will be conducted in 2 parts: Part A: Single ascending intravenous (IV) doses of CBS001 Part B: Multiple ascending IV doses of CBS001

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Chronic Inflammatory Disease

• NCT number: NCT05323110
• Study type: Interventional
• Source: Capella Bioscience Ltd
• Status: Terminated
• Phase: Phase 1
• Start date: April 14, 2022
• Completion date: August 22, 2023